Atera must convert 10x Genomics’ scientific leadership into durable clinical growth before patent erosion and premium valuation risk catch up.
Overview
10x Genomics is a premium life sciences tools company enabling single-cell and spatial analysis for oncology, immunology, neuroscience, and translational research. Its razor-and-blade model is dominated by recurring consumables, which generated $507.2 million of FY2025’s $642.8 million revenue. Academic and government labs drive roughly 65% of sales, while biopharma adds about 30%. The company benefits from strong scientific validation, over 7,500 cited publications, and deep workflow adoption, but faces slowing instrument demand, funding sensitivity, and rising competitive pressure.